This study shows that while common senolytic compounds are unable to eliminate CDK4/6i-treated malignant cells, CDK4/6i elicits lysosome alterations that render breast cancer cells susceptible to combined therapy. This evidence concerns the gene CDK4 and breast carcinoma.